To include your compound in the COVID-19 Resource Center, submit it here.

Seattle Genetics reports Phase I data for TNBC candidate

Seattle Genetics Inc. (NASDAQ:SGEN) reported data from 60 evaluable patients with metastatic triple-negative breast cancer (TNBC) in a Phase I trial

Read the full 216 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE